<DOC>
	<DOCNO>NCT01679132</DOCNO>
	<brief_summary>The BAROSTIM NEO HTN trial prospective , randomize , control trial demonstrate safety efficacy Barostim Neo system subject resistant hypertension . Currently , BAROSTIM NEO HTN trial actively enrol . CVRx conduct long-term follow-up patient implant BAROSTIM NEO device . This update do subject protection concern would preclude continuation investigation .</brief_summary>
	<brief_title>BAROSTIM NEO HTN Pivotal Trial</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Inclusion Criteria Highlights : Age least 21 year 80 year time randomization . On four maximally tolerate antihypertensive medication , one diuretic . The antihypertensive medication regimen must remain unchanged 4 week prior screen must expect remain unchanged least 6 month followup . Protocol define systolic blood pressure great equal 160 mmHg . Protocol define 24hour Ambulatory Blood Pressure Monitoring ( ABPM ) great equal 135 mmHg . Serum estimate glomerular filtration rate ( eGFR ) &gt; 29 mL/min/1.73 m^2 . Appropriate surgical candidate . Women childbearing potential must use medically accept method birth control agree continue use method duration study . Women childbearing potential must negative pregnancy test within 14 day prior randomization . Exclusion Criteria Highlights : Known suspect baroreflex failure autonomic neuropathy . Myocardial infarction , hypertensive crisis , symptomatic orthostatic hypotension , unstable angina , syncope , cerebral vascular accident within 3 month . Hypertension secondary identifiable treatable cause sleep apnea . Prior surgery , radiation , endovascular stent placement carotid sinus region .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>High Blood Pressure</keyword>
	<keyword>Blood Pressure</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Resistant Hypertension</keyword>
</DOC>